Researchers have shown that ANGLE PLC’s (LON:AGL) Parsortix liquid biopsy system can be used to identify people with glioblastoma – an aggressive type of brain cancer.
Parsortix detects and captures circulating tumour cells (CTCs), which provide the tell-tale signs of cancer and their capture can allow doctors to more accurately assess treatment options.
It had previously been thought that clusters of CTCs in brain cancers would not pass through the blood-brain barrier meaning ANGLE’s system wouldn’t have been able to detect them.
But a team of scientists from the University of Basel in Switzerland has disproved that theory, showing that as well as singular CTCs, clusters of CTCs will pass through the blood-brain barrier and can be harvested for analysis using the Parsortix system.
“The glioblastoma work is a further example of ground breaking research being undertaken by a Parsortix customer in addition to ANGLE's own efforts to commercialise the Parsortix system,” said chief executive Andrew Newland.
“University of Basel and their collaborators are working on the application of this approach for the treatment of glioblastoma patients and we look forward to reporting further developments in due course.”
Shares rose 5.2% in early deals on Tuesday to 48.9p.